ArticleBioData mining2026
CME-KGDTI: integrating clustered mutations into knowledge graph embedding for drug-target interaction prediction.
Article in BioData mining, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundComputational prediction of drug-target interaction (DTI) is critical for drug discovery and precision medicine. Herein, we constructed a biologically enriched heterogeneous knowledge graph (KG) integrating clustered mutations, synthetic lethal interactions, drug structures, protein sequences, and functional annotations. This multi-dimensional framework was designed to enable the identification of actionable diagnostic signatures and precision therapeutic strategies by leveraging multi-layered biological network factors.
resultsEntities within the KG were embedded into low-dimensional vectors using various graph embedding techniques (TransE, RotatE, DistMult, Node2vec and R-GCN). These multimodal embeddings served as input for deep learning models (DNN, NFM, AutoInt), with standardization and PCA-based dimensionality reduction applied. Under a challenging protein cold-start scenario, the CME-KGDTI model demonstrated a better performance. These results highlight the multi-source biological information in enhancing positive sample identification and overall model generalization. Additionally, the CME-KGDTI platform ( https://www.tmliang.cn/cmekgdti/#/home ) was developed, integrating resources for clustered mutation identification, cancer-specific SL-based genetic networks, DTI prediction, and multi-omics analysis, enabling users to comprehensively explore mutation detection, target prioritization, and mechanistic insights.
conclusionsBy incorporating biological features, the CME-KGDTI model exhibits high accuracy and robust generalization, highlighting its essential complementary role in drug target discovery. The developed CME-KGDTI platform will serve as a flexible, interactive, and implementable technical support platform, contributing to the advancement of precision oncology research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.